Phase 1Completed

Bioequivalence Study of Two Products of Tenofovir Alafenamide 25 mg Film Tablet in Healthy, Adult, Human Subjects

An Open Label, Balanced, Randomized, Two-sequence, Two-treatment, Four -Period, Single Oral Dose, Fully Replicate,Bioequivalence Study in Normal, Healthy, Adult, Human Subjects Under Fed Condition.

Sponsor
Humanis Saglık Anonim Sirketi (Industry)
Enrollment
42 enrolled
Conditions
Chronic Hepatitis B in Adults and Paediatric Patients
Interventions
Tenofovir Alafenamide Film coated Tablet; Vemlidy® film-coated tablets
Ages
adults
Registry
NCT06592300

Full record on ClinicalTrials.gov

From the registry

To compare the bioavailability and characterize the pharmacokinetic profile of the sponsor's test product relative to that of reference product after single oral dose, fully replicate, bioequivalence study in normal, healthy, adult, human subjects under fed condition.

Primary outcomes

  • Maximum plasma concentration (Cmax)
  • AArea under the plasma concentration curve from administration to last observed concentration at time t (AUC0-t)

History

  1. Last registry update

  2. Registered

  3. Study completion

  4. Primary completion

  5. Started